Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook

The Fertility Show, Manchester Central, 24-25 March 2018


First clinical grade, 'gold standard' stem cells created

12 December 2011

By Victoria Kay

Appeared in BioNews 637

The world's first 'clinical grade' human embryonic stem cells have been donated to the UK Stem Cell Bank (UKSCB). The high quality cell lines are expected to become the gold standard for developing new cell-based therapies for serious medical conditions, including spinal cord injuries.

The cells are unique because, unlike 'research grade' cell lines, they have been created without the help of animal products, which are normally used to stimulate cell growth. These 'xeno-free' cells have been described as the 'holy grail' of regenerative medicine.

'We have succeeded where many substantial commercial companies have not', said researcher Professor Peter Braude of King's College London, UK. 'We had to get to the point where everything we're using is animal free, or in some way has been tested to be safe or its provenance known – you can't have something that has been exposed to pig, mouse or cow injected into humans. The 'holy grail' is where you start the [cell] line from the point where it is clean enough to be used for clinical therapy – all the ingredients are clean'.

Some research grade cell lines have previously been re-classified as clinical grade following a vigorous conversion process to remove all traces of animal products. Such re-classified cells are currently being tested in small safety trials but their use is highly restricted and the associated risks are deemed unacceptable for widespread human use.

The ten-year-long research was funded by the UK's Medical Research Council (MRC) and conducted to strict European ethical and quality standards. This means the cells could soon be made available to any European researchers who wish to use them. However, before this can happen the UKSCB will conduct a comprehensive series of tests to ensure the cells are safe for use in humans.

'These lines will be an important resource to fulfil our plan to make available a panel of characterised and tested clinical grade lines within the next three years. The process of testing will be rigorous and not all cells lines received will make the grade', said Dr Glyn Stacey, head of the UKSCB. 'The moment we release them they are ready for use in a clinical trial'.

Dr Rob Buckle, head of regenerative medicine at the MRC, added: 'The development of xeno-free human embryonic stem cells lines is a major step forward in the field as it paves the way for 'gold standard' clinical-grade cell lines suitable for use in humans'.

Financial Times | 06 December 2011
Telegraph | 06 December 2011
Channel 4 News | 06 December 2011
Eurekalert | 06 December 2011
Nature News | 06 December 2011
Press Association | 07 December 2011


12 November 2012 - by Dr Rachael Panizzo 
The Wellcome Trust and Medical Research Council have announced a £12.75 million investment to create a database of induced pluripotent stem) cells....
02 July 2012 - by Ruth Retassie 
The University of Massachusetts (UMass) Stem Cell Bank, opened in response to restrictions on the funding of human embryonic stem cell (hESC) research in the USA, will close after just four years in existence when it runs out of public funding later this year....

21 November 2011 - by Victoria Kay 
The world's first clinical trial using patients' own cardiac stem cells to repair heart damage has produced surprising results. The preliminary trial was designed simply to test the safety of the procedure, but doctors observed an unexpected improvement in heart function in patients receiving the treatment...
19 September 2011 - by Antony Blackburn-Starza 
A new fund to help pay for stem cell research in Scotland has been launched. The UK Stem Cell Foundation (UKSF) will aim to raise £5 million over three years to support the work of researchers and clinicians in Scotland into treatments and cures for illnesses including diabetes, strokes, multiple sclerosis, blindness and Alzheimer's disease...
01 June 2009 - by Antony Blackburn-Starza 
New proposed embryonic stem (ES) cell research guidelines in the US are coming under fire from critics who are concerned that the rules will in fact hamper research in this area. The National Institutes of Health (NIH) has collected over 20,000 responses to its public consultation on...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation